A study of mefloquine treatment for progressive multifocal leukoencephalopathy: Results and exploration of predictors of PML outcomes

Journal of NeuroVirology

Volumn 19, Issue 4, 2013, Pages 351-358

  Clifford, David B ^a   Nath, Avindra ^b   Cinque, Paola ^c   Brew, Bruce J ^d,h   Zivadinov, Robert ^e,i   Gorelik, Leonid ^f   Zhao, Zhenming ^g   Duda, Petra ^f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY AT BUFFALO   (United States)

^f BIOGEN   (United States)

^g Pharmaceutical Product Development   (United States)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ JACOBS NEUROLOGICAL INSTITUTE   (United States)

Author keywords

JC virus; Leukoencephalopathy; Magnetic resonance imaging; Mefloquine; Progressive multifocal

Indexed keywords

MEFLOQUINE; VIRUS DNA;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; EXPLORATORY RESEARCH; FEMALE; GENE DOSAGE; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JC VIRUS; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIMALARIALS; ANTIVIRAL AGENTS; BRAIN; DNA, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MALE; MEFLOQUINE; MIDDLE AGED; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84883481860     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-013-0173-y     Document Type: Article

References (12)

1. Berger JR (2011) The clinical features of PML. Cleve Clin J Med 78(suppl 2):S8-S12
2. Bossolasco S, Calori G, Moretti F, Boschini A, Bertelli D, Mena M, Gerevini S, Bestetti A, Pedale R, Sala S, Sala S, Lazzarin A, Cinque P (2005) Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 40:738-744
3. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A (2010) Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 6:667-679
4. Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, Frisque RJ, Gorelik L (2009) Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 53:1840-1849
5. Delbue S, Elia F, Carloni C, Tavazzi E, Marchioni E, Carluccio S, Signorini L, Novati S, Maserati R, Ferrante P (2012) JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy. J Cell Physiol 227:3511-3517
6. Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, Major EO (2012) Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 25:471-506
7. Gasnault J, Costagliola D, Hendel-Chavez H, Dulioust A, Pakianather S, Mazet AA, de Goer de Herve MG, Lancar R, Lascaux AS, Porte L, Delfraissy JF, Taoufik Y, ANRS 125 Trial Team (2011) Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One 6:e20967
8. Koralnik IJ (2006) Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 60:162-173
9. Roche Laboratories Inc. (2003) Lariam (mefloquine) [prescribing information]. Roche Laboratories, Nutley. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/label/2003/19591slr022-lariam-lbl.pdf. Accessed 18 Apr 2012
10. Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Rhein HG (2010) The position of mefloquine as a 21st century malaria chemoprophylaxis. Malaria J 9:357
11. Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:425-437
12. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M (2001) Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57:1239-1247